Inflammasomes in neuroinflammation and changes in brain function: a focused review by Gaurav Singhal et al.
REVIEW ARTICLE
published: 07 October 2014
doi: 10.3389/fnins.2014.00315
Inflammasomes in neuroinflammation and changes in
brain function: a focused review
Gaurav Singhal1, Emily J. Jaehne1, Frances Corrigan2, Catherine Toben1 and Bernhard T. Baune1*
1 Psychiatric Neuroscience Lab, Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, SA, Australia
2 Discipline of Anatomy and Physiology, School of Medical Sciences, University of Adelaide, Adelaide, SA, Australia
Edited by:
Luba Sominsky, RMIT University,
Australia
Reviewed by:
Trisha Anne Jenkins, RMIT
University, Australia
Ruth M. Barrientos, University of
Colorado, USA
*Correspondence:
Bernhard T. Baune, Psychiatric
Neuroscience Lab, Discipline of
Psychiatry, School of Medicine,
University of Adelaide, Level 4,
Eleanor Harrald Building, North
Terrace, Adelaide, SA - 5005,
Australia
e-mail: bernhard.baune@
adelaide.edu.au
Recent literature has pointed to the existence of inflammasome-mediated inflammatory
pathways in central nervous system (CNS) disorders and associated changes in behavior.
Neuroinflammation, which is an innate immune response in the CNS against harmful and
irritable stimuli such as pathogens and metabolic toxic waste, as well as to chronic mild
stress, is mediated by protein complexes known as inflammasomes. Inflammasomes
activate pro-inflammatory caspases 1 and 5, which then cleave the precursor forms
of pro-inflammatory cytokines IL-1β, IL-18, and IL-33 into their active forms. These
pro-inflammatory cytokines have been shown to promote a variety of innate immune
processes associated with infection, inflammation, and autoimmunity, and thereby play an
instrumental role in the instigation of neuroinflammation during old age and subsequent
occurrence of neurodegenerative diseases, cognitive impairment, and dementia. In
particular, NLRP inflammasomes may also have a role in the etiologies of depression,
Alzheimer’s disease (AD) and in metabolic disorders, such as Type II diabetes, obesity
and cardiovascular diseases that have been shown to be co-morbid with psychiatric
illnesses. It has been reported that while these inflammasomes may be activated
through TNF-α dependent pathways, other cytokines, like IFN-γ, may assist in inhibiting
their activation and thus delay disease progression. Furthermore, some other cytokines,
including IL-6, may not have a direct role in inflammasome-mediated diseases. An array of
recent research suggests that NLRP inflammasomes targeted therapies could be used
for alleviating neuroinflammation and for treatment of associated psychiatric illnesses,
although this still remains a challenge and necessitates further extensive research. This
review examines the complex inflammatory signaling pathways involved in the activation
of NLRP inflammasomes and the role they play in promoting neuroinflammation and
subsequent behavioral changes.
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INTRODUCTION
The discovery of inflammasomes by Martinon et al. (2002) has
prompted considerable interest in the role that inflammasomes
play in the mechanism of inflammation and associated disease
patterns. Of late, an emerging body of literature points to the
existence of inflammasome-mediated inflammatory pathways in
central nervous system (CNS) disorders.
Neuroinflammation is a known factor in the pathogenesis
of neurodegenerative diseases (Frank-Cannon et al., 2009), and
psychiatric illnesses such as depression (Walker et al., 2014),
Alzheimer’s disease (AD) (Pimplikar, 2014), Parkinson’s dis-
ease (PD) (Hirsch et al., 2012), Huntington’s disease (Möller,
2010), and multiple sclerosis (Frohman et al., 2006). It has also
been implicated in sickness behavior (Biesmans et al., 2013),
diminished cognition (Ownby, 2010), and memory (Hein and
O’Banion, 2009), as well as in age-related increased sensitiza-
tion of the immune system to extrinsic and intrinsic stimuli
(Godbout et al., 2005; Sparkman and Johnson, 2008). Pattern
recognition receptors (PRRs) play an integral role in the innate
immune response through recognition of pathogen specific pro-
teins (PAMPs) and damage associated proteins (DAMPs). They
are primarily expressed by glial cells, macrophages and oligoden-
drocytes within the brain and can be membrane bound (toll-like
receptors) or within the cytoplasm [Nod-like receptors (NLRs)].
Activation of these NLRs leads to the assembly and activation of
cytosolic protein complexes known as inflammasomes which then
enable the activation of pro-inflammatory caspases, particularly
caspase-1. This then leads to the activation of pro-inflammatory
cytokines interleukin (IL)-1β, IL-18, and IL-33 (Arend et al.,
2008; Chakraborty et al., 2010), which promote a number of
innate immune processes associated with infection, inflamma-
tion and autoimmunity (Davis et al., 2011), thereby responsible
for neuroinflammation and associated brain diseases (Tha et al.,
2000; Cacquevel et al., 2004; Felderhoff-Mueser et al., 2005;
Godbout and Johnson, 2009;Mawhinney et al., 2011; Zhang et al.,
2014).
It has been known for some time that immunosenescence,
in addition to neurodegenerative changes with age, predisposes
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the brain to higher risk of acquiring neuroinflammatory disor-
ders. Considerable findings during the last decade have suggested
an instrumental role of inflammasomes in the pathophysiol-
ogy of neuroinflammation during neuronal ageing, and its
associated neurodegenerative diseases such as dementia, lead-
ing to loss of memory and cognitive impairment (Simi et al.,
2007; Chakraborty et al., 2010; Mawhinney et al., 2011; Liu
and Chan, 2014). In particular, NLRP (NLR family, contain-
ing pyrin domain) inflammasomes have been shown to have
a role in the etiologies of several neurological diseases such
as depression (Zhang et al., 2014), AD (Tan et al., 2013), PD
(Cedillos, 2013), and multiple sclerosis (Gris et al., 2010; Fischer
et al., 2012). Systemically, NLRP inflammasome-driven inflam-
matory responses also play a role in the development of Type
II diabetes (Grant and Dixit, 2013; Lee et al., 2013), obe-
sity (Stienstra et al., 2011), and cardiovascular diseases (Garg,
2011), as well as cancer (Zitvogel et al., 2012). Given that
metabolic disorders can predispose to the development of psychi-
atric disorders, it is possible that inflammasome-driven inflam-
matory pathways may be a potential mechanism driving this
co-morbidity.
A number of studies have investigated the innate immune
pathways associated with the activation of NLRP inflamma-
somes and the subsequent production of IL-1β, IL-18, and IL-33
from their precursors. The aim of this review is to examine
these complex inflammatory signaling pathways associated with
NLRP inflammasomes activation, and leading to neuroinflamma-
tion and behavioral changes that have commonly been observed
during various psychiatric disorders and brain aging.
MATERIALS AND METHODS
PRISMA CRITERIA
The guidelines prescribed by PRISMA (Preferred reporting items
for systematic reviews and meta-analyses) (Liberati et al., 2009;
Moher et al., 2009) were followed while constructing this review.
The checklist items from PRISMA as relevant to this review, for
example those related to search and writing approaches, were
included and the items not relevant, for example those related to
meta-analyses, were excluded.
SEARCH AND SELECTION PROCESS
An electronic database search of PubMed and Google Scholar
with several key terms in various permutations was performed.
These included but were not limited to: inflammasomes, neu-
roinflammation, NLRP, NALP (NACHT, LRR, and PYD domains
containing proteins), cytokines, IL-1, IL-18, IL-33, TNF, cellular,
humoral, immune, aging, depression, AD, PD, Huntington’s dis-
ease, multiple sclerosis, cognition, behavior, metabolic disorders,
diabetes, obesity, cardiovascular disease, cancer, pathogen associ-
ated molecular patterns, damage associated molecular patterns,
toll like receptors, and glial cells. At each stage of the search, titles
and abstracts were scrutinized and the most appropriate orga-
nized into separate folders using End Note X6.0.1 software. In
addition, articles relevant to our discussion were retrieved from
the reference list of other online articles on each subtopic. This
in total yielded 1563 papers. After placing all inclusion and exclu-
sion criteria into our search (depicted in Figure 1), 164 articles
closely related to the aims set forth for this review were selected
and hence utilized.
INCLUSION AND EXCLUSION CRITERIA
The emphasis of this review has been on inflammatory pathways
associated with inflammasome activity in the brain, and as such
articles investigating inflammasomes, in particular NLRP inflam-
masomes and their mechanism of actions in CNS disorders were
selected for detailed analysis. In addition, articles addressing the
effects of IL-1 family of cytokines in the brain were read thor-
oughly to understand and analyze the various mechanisms of
actions of these cytokines, especially in the brain and their asso-
ciation with inflammasomes. Other immune factors related to
inflammasomes and the role of inflammasomes in systemic dis-
eases was also investigated while writing this review. All articles
included in this review have been published between 1989 and
2014. Articles without the full text available and with anecdotal
evidence were excluded from the review.
STRUCTURE OF NLRP INFLAMMASOMES
The NLR family, pyrin domain containing inflammasomes
(NLRP) are the most studied and best characterized protein
complex during inflammation (Stutz et al., 2009). NLRs are intra-
cellular PRRs and function in association with Toll-Like Receptors
to sense the presence of PAMPs which are found in a variety
of microorganisms that enter cell through phagocytosis (infec-
tious stimuli), and DAMPs such as nuclear and cytosolic protein
characteristics of tissue injury/stress (non-infectious stimuli). In
turn, this activates the innate and acquired immune response
(Inohara et al., 2005; Kanneganti et al., 2007; Franchi et al.,
2009). A key part of this process is the assembly of inflamma-
some complexes that generally have three main components: a
cytosolic PRR (either from the NLR family or the pyrin and HIN
domain containing family-PYHIN), caspase-1 and an adaptor
protein ASC (apoptosis-associated speck like protein). The NLR
family contains a leucine rich repeat domain (LRR), a central
NACHT domain and a variable amino-terminal domain, which
in the NLRP subfamily is an N-terminal pyrin domain (PYD).
Activation of NLRPs leads to the recruitment of ASC which
contains a caspase activation and recruitment domain (CARD).
ASC then interacts with the CARD of pro-caspase-1. There are
exceptions to this sequence, with for example NLRP1, directly
interacting with pro-caspase 1, without necessarily needing ASC.
Nonetheless the interaction with pro-capse-1 leads to its conver-
sion to caspase 1, which then converts pro forms of IL-1β, IL-18,
and IL-33 into their active forms, initiating an inflammatory
response (Martinon et al., 2002; Petrilli et al., 2005).The NLRP3
is the largest and most studied inflammasome of all known at this
stage (Stutz et al., 2009).
See Figure 2 for the schematic representation of the structures
of different NLRP inflammasomes as described above.
THE ROLE OF IL-1 FAMILY OF CYTOKINES IN
INFLAMMATION, PATHOLOGICAL STATES, AND
HOMEOSTATIC RESPONSE IN THE BRAIN
Pro-inflammatory cytokines function to attract leucocytes and
enhance their proliferation at the site of inflammation. They
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FIGURE 1 | Study inclusion flowchart. It depicts the methodology for search and collection of relevant articles for this review, following PRISMA guidelines
(Liberati et al., 2009; Moher et al., 2009).
FIGURE 2 | Structure of NLRP inflammasomes. NLRP inflammasomes
are intracellular protein complexes consisting of NLRP (NACHT, LRR, and
PYD domains containing proteins 1, 2, or 3), the adapter protein
ASC/Pycard, enzyme pro-caspases 1 and 5, and cardinal proteins. NLRP1
has Pyrin (PYD) domain on the amino (N)-terminal. This PYD domain is
bonded to a NACHT domain followed by a NACHT-associated domain
(NAD), several lucine-rich repeats (LRR), FIIND domain and the caspase
recruitment domain (CARD) at the carboxy (C)-terminal. The molecular
structures of NLRP2 and NLRP3 are similar to NLRP1, except that
instead of being directly linked to FIIND domain, LRRs are linked to a
cardinal protein which consists of FIIND domain on N-terminal and CARD
domain on the C-terminal. NLRPs with the adapter protein ASC/Pycard
and pro-caspase enzymes form the inflammasome complex responsible
for converting pro-IL-1 cytokines into their active forms within the
cytoplasm of glial cells primarily. ASC, apoptosis-associated speck-like
protein containing a CARD.
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stimulate cytotoxicity, release of proteolytic enzymes, synthe-
sis of prostaglandins, and synthesis and secretion of secondary
cytokines. This in turn promotes inflammation and increases
thermoregulatory set point, generally associated with symptoms
such as fever, tissue destruction, shock, and even death (Cannon,
2000). The IL-1 family of cytokines comprises 11 secreted fac-
tors, including IL-1α, IL-1β, IL-18, and IL-33, which are known
for playing a role in host defense and immune system regula-
tion in inflammatory diseases (Barksby et al., 2007; Arend et al.,
2008; Dinarello, 2009; Sims and Smith, 2010). These cytokines
have been shown to be involved in a variety of immune reac-
tions as well as in the initiation, regulation, and maintenance
of inflammation (Dinarello, 2000). In particular, cytokine medi-
ated processes have been shown to result in long term neu-
ropsychiatric disorders and were found to be related to major
depression, dementia, and AD (Licastro et al., 2000; Cacquevel
et al., 2004; McAfoose and Baune, 2009). The presence of IL-
1β has been demonstrated in cerebrospinal fluid and plasma of
patients with AD (Licastro et al., 2000; Tarkowski et al., 2003).
Similarly, the roles of IL-18 and IL-33 in neuroinflammation
and neurodegenerative diseases have also been well established
(Felderhoff-Mueser et al., 2005; Arend et al., 2008; Liew et al.,
2010).
However, it is important to note that although pro-
inflammatory cytokines (IL-1 and TNF family of cytokines) have
been shown to result in neuroinflammation and neurodegenera-
tive diseases when expression is high, at constitutive levels they
are required for normal physiological functioning, particularly
in the molecular and cellular mechanisms responsible for learn-
ing, memory and cognition (McAfoose and Baune, 2009). They
influence and maintain homeostasis in monoamine metabolism,
neuronal genesis and survival, Hypothalamic-Pituitary-Adrenal
(HPA) axis sensitivity to cortisol and certain cellular neuroim-
mune functions (Eyre and Baune, 2012). However, levels of both
pro-inflammatory and anti-inflammatory cytokines have been
shown to be elevated in many brain disorders, including AD, PD,
and age related dementia, indicating their role in cognitive and
memory deficits with age. When pro-inflammatory cytokines are
overexpressed, anti-inflammatory cytokines potentially function
to suppress the gene expression for pro-inflammatory cytokine
production and control the pro-inflammatory response. For
instance, gene knockout mice for anti-inflammatory cytokines,
such as IL-1ra, IL-10, and TGF-β1 showed enhanced inflamma-
tory reactions (Dinarello, 2000). However, no study describes the
effects of anti-inflammatory cytokines on activated inflamma-
somes. Activated microglia and astrocytes are the main source of
cytokines in the brain (Rothwell et al., 1996; Hanisch, 2002).
Figure 3 shows the cytokine cascade in brain following stimu-
lation with an infectious agent, metabolic waste or foreign mate-
rial. As this includes increase in the levels of IL-1β cytokine which
can only be activated from its precursor in the presence of enzyme
caspase 1, it indicates an active involvement of inflammasome
action during this cytokine cascade.
LINK BETWEEN AGING OF BRAIN, IL-1 CYTOKINES, AND BRAIN
DISORDERS
Aging of the brain has been shown to be associated with many
cognitive and memory deficit disorders and is believed to be
regulated by extrinsic (e.g., environmental) and intrinsic (e.g.,
genotype) factors (van der Staay, 2002). Several brain disorders,
such as AD and PD, are the products of chronic neuroinflam-
mation and resultant neurodegeneration (Heneka et al., 2010;
Hirsch et al., 2012), the symptoms which are also common to the
aging brain (McGeer and McGeer, 2004). Dementia, decline in
cognitive abilities and impairment of spatial memory are often
seen during aging and are associated with neuroinflammatory
changes within the brain accumulated over a period of time.
Indeed, a significant association has been found between age
related depression and level of pro-inflammatory cytokines in
the brain (Godbout et al., 2008). Moreover, the risk of infections
increases with age, mainly due to immunosenescence (Aw et al.,
2007) and a rise in circulating autoantibodies and lymphopro-
liferative disorders, hence contributing toward greater morbidity
andmortality in old age (Shinkai et al., 1998; Senchina and Kohut,
2007).
Structural and functional changes in the brain are coordi-
nated by a range of intracellular signaling molecules. Consistent
findings suggest that an increase in the expression of pro-
inflammatory cytokines by astrocytes and microglia within the
brain results in neuroinflammation followed by neurodegener-
ation, eventually resulting in cognitive and memory deficit and
exacerbated sickness and depressive-like behavior (Mrak and
Griffin, 2005; Huang et al., 2008). Microglia are primed with
aging and upon secondary stimulation, these microglia release
excessive quantities of pro-inflammatory cytokines, such as TNF-
α, IL-1β, and IL-6 (Dilger and Johnson, 2008). The increase in
the number of microglia, astrocytes and percentage of GFAP in
the brain with age has been reported in rodents, which is subse-
quently found to be related to cognitive and memory impairment
(Sugaya et al., 1996; Rozovsky et al., 1998), and to neurode-
generative diseases such as AD (Mrak and Griffin, 2005). The
effects of aging on microglial functions in the brain has been
reviewed in detail by Conde and Streit (2006). During aging, glial
cells, particularly microglia show increased activation and expres-
sion of pro-inflammatory cytokines, such as IL-1, however, they
also become increasingly dysfunctional and lose neuro-protective
properties which predispose the brain to the neurodegenerative
disorders in line with other genetic and acquired environmental
risks (Mrak and Griffin, 2005; Streit, 2005). Similarly, astrocytes
are the immune effector cells, which express cytokines (IL-1, IL-
6, IL-10, interferons α and β, TNF α and β) and chemokines, and
mediate inflammation and immune reactivity in the brain. The
under-expression or over-expression of astrocytes can also lead to
neurodegenerative diseases (Dong and Benveniste, 2001).
INFLAMMASOME MEDIATED INFLAMMATORY PATHWAYS IN THE
AGING BRAIN
It was not known until recently whether inflammasomes play
any role in causing or aggravating neuroinflammation during
neuronal aging. Considerable recent findings have suggested
an instrumental role of inflammasomes in the pathophysiology
of neuroinflammation during neuronal ageing, and associated
neurodegenerative diseases, cognitive impairment and demen-
tia (Simi et al., 2007; Chakraborty et al., 2010; Mawhinney
et al., 2011; Liu and Chan, 2014). There is upregulation in the
expression of several genes that signal inflammasome assembly
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FIGURE 3 | Inflammasomes Cascade in Brain. On recognizing
pathogen associated molecular patterns (PAMPs, found in phagocytized
microorganisms) and damage associated molecular patters (DAMPs,
e.g., nuclear and cytosolic proteins), intracellular pathogen recognition
receptors (PRRs) and Toll-Like Receptors (TLRs) initiates assembly of
cytosolic inflammasome complex. In turn, this activates the innate
and acquired immune responses involving Interleukin (IL)-1 cytokines,
which in addition to Tumor Necrosis Factor (TNF)-α initiate
inflammatory reaction in the extracellular space. PC1 and PC5,
Pro-caspases 1 and 5; C1, Caspase 1.
and activation of caspase 1 (e.g., thioredoxin-interacting pro-
tein, P2X7, and pannexins), as well as signaling of TLRs (e.g.,
CD14, TLR2, TLR4, TLR7, TOLLIP, MYD88) in different regions
of the brain such as hippocampus, post-central gyrus, and supe-
rior frontal gyrus during aging (Cribbs et al., 2012). TLRs
are evolutionary conserved microbe specific structural motifs
(e.g., PAMPs) and endogenous molecule (e.g., DAMPs) recog-
nition transmembrane or endosomic membrane proteins, pri-
marily expressed in various sentinel cells such as dendritic cells,
macrophages, and plasmatoid dendritic cells that form the first
line of defense (Kumar et al., 2009). The interaction between
TLRs and LRRs on cytosolic NLRs trigger the assembly and acti-
vation of inflammasomes culminating in caspase 1 catalyzing
pro-IL-1 cytokines into their active forms (van de Veerdonk and
Netea, 2011). The increased activity of both TLRs and NLRs
in the aging brain can therefore act as a deterrent to the neg-
ative regulation of their expression and a sustained expression
could result in chronic neuroinflammation and associated neu-
rodegenerative diseases. Moreover, production of reactive oxygen
species (ROS) from dysfunctional mitochondria and increased
NF-κB signaling with aging could also potentiate the priming
of NLRP3 inflammasomes in the brain resulting in an inflam-
matory response (Salminen et al., 2012). Formation of mutant
α-synuclein and Aβ fibrils, seen during PD and AD respectively,
further pose greater danger in old age as they act to enhance the
activity of inflammasomes in the brain (Salminen et al., 2009;
Tschopp and Schroder, 2010; Cedillos, 2013).
Enhanced inflammasome activity could manifest in the form
of cognitive decline in an aging population, as shown in 18month
old male Fisher 344 rats, however spatial learning improved when
rats were treated with an anti-inflammatory drug probenecid
(Mawhinney et al., 2011) which reduced NLRP1 inflammasome
activation. However the mechanism for this is not yet completely
understood.
ASSOCIATION BETWEEN NEUROINFLAMMATION AND
MAJOR DEPRESSIVE DISORDER
Major depressive disorder (MDD) is characterized by a distinct
change of mood accompanied by sadness, irritability, loss of
interest in all activities and events, as well as psychophysiologi-
cal changes (Belmaker and Agam, 2008). A number of studies,
both experimental and meta-analytic, have revealed increased
expression of pro-inflammatory cytokines, TNF-α, IL-1β, and
IL-6, in the brain of MDD patients leading to neuroinflamma-
tion (Maes et al., 1997; Howren et al., 2009; Dowlati et al., 2010;
Hannestad et al., 2011). Role of chronic mild stress in neuroin-
flammation and subsequent occurrence of depression has also
been established (Farooq et al., 2012), although it is not clear if
inflammasomes have any role in causing neuroinflammation in
response to chronic mild stress.
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INFLAMMASOME MEDIATED INFLAMMATORY PATHWAYS
ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER
The increase in IL-1β levels and neuroinflammation in the brain
of MDD patients potentially suggests a role for inflammasomes
in MDD. Researchers have indeed recently shown the involve-
ment of the NLRP3 inflammasome in lipopolysaccharide (LPS)-
induced mouse depressive-like behavior (Zhang et al., 2014).
Similar findings were seen in human participants when activated
NLRP3 inflammasomes were detected in bloodmononuclear cells
from depressive patients (Alcocer-Gómez et al., 2014). To inves-
tigate the etiological role of inflammasomes in depression, a
panel of researchers conducted a clinical trial in major depres-
sion and schizophrenic patients. They concluded from the study
that inflammasome-related inflammation is an ongoing process
in psychiatric patients during diseased states (Hohmann et al.,
2014). Moreover, the recent finding that mice lacking caspase-
1 are resistant to LPS-induced depressive-like behavior further
supports the role of inflammasomes in depression (Moon et al.,
2009). Some authors recently reviewed the role of inflammasomes
in MDD and its comorbidity with systemic illnesses, and pro-
posed a new inflammasome hypothesis of depression and related
comorbid systemic illnesses (Iwata et al., 2013). The review high-
lights the central mediator role that inflammasomes play in the
contribution of psychological and physical stressors to the devel-
opment of depression and its association with systemic illnesses.
The activation of inflammasomes, particularly NLRP3, therefore
could be indirectly related to the pathophysiology of depres-
sion and its comorbidity with other systemic diseases through an
inflammatory response in the brain.
ASSOCIATION BETWEEN NEUROINFLAMMATION AND
ALZHEIMER’S DISEASE
AD is characterized by a debilitating chronic and progressive
neurodegeneration leading to major clinical hallmarks of loss of
memory, cognitive deficit, dementia, and behavioral impairment.
Although, the prevalence of AD is higher in people over 60 and it
increases proportionally with every 10 years of age (Younger/Early
Onset Alzheimer’s and Dementia: Alzheimer’s Association, 2014),
early onset of AD has also been reported in people in their 40s and
50s (Kim et al., 2014). Several factors such as genetic predispo-
sition (Bertram and Tanzi, 2009; Kamboh et al., 2012), reduced
synthesis of excitatory neurotransmitter acetyl choline (Babic,
1999), extracellular deposition of amyloid beta (Aβ) in the brain
(Palop and Mucke, 2010), abnormalities in tau protein forming
neurofibrillary tangles leading to disintegration of microtubules
(Ballatore et al., 2007), and oxidative stress and inflammatory cas-
cades mediated by primed glia cells (Agostinho et al., 2010) have
been proposed to cause AD. These different hypotheses have been
established after years of independent research; however, recent
efforts toward finding the common link between the causal fac-
tors for AD have pointed toward the inflammatory cascade link-
ing them in the brain. Indeed, damaged neurons, highly insoluble
Aβ deposits and neurofibrillary tangles could provide stimuli for
neuroinflammation (Wenk, 2003). Similarly, neurotransmitter
acetylcholine has been shown to be involved in inhibiting the
release of pro-inflammatory cytokines frommicroglia andmono-
cytes (Tabet, 2006), an anti-inflammatory mechanism that could
be disturbed during acetylcholine deficiency. This suggests that all
above etiologies for AD, when accompanied by chronic neuroin-
flammation, lead to progressive neurodegeneration and behav-
ioral impairment with age, characteristics of symptoms of AD. In
the absence of neuroinflammation, these etiologies may not pro-
vide sufficient pathology to cause AD. This is supported by the
finding that significant amyloid deposition could be present in
the brain of healthy elderly individuals without cognitive impair-
ment (Aizenstein et al., 2008). Likewise, while higher quantities
of tau proteins have been reported in the brain of AD patients
than unaffected individuals (Avila et al., 2004), some authors
have challenged the tau protein hypothesis and proposed that tau
phosphorylation is a compensatory mechanism to protect neu-
rons against oxidative stress (Lee et al., 2005). Nonetheless, this
suggests overall that a single factor alone may not be sufficient to
cause AD, and irrespective of the causative factor, neuroinflam-
mation essentially provides a central pathway to the onset of AD
which is mediated by various pro-inflammatory cytokines and
chemokines, including IL-1 family of cytokines that are activated
by inflammasomes.
Indeed, IL-1β and IL-18 over-expression has been shown to
initiate inflammatory process in the brain of AD patients (Rubio-
Perez and Morillas-Ruiz, 2012; Liu and Chan, 2014). This over-
expression has been detected in microglia, astrocytes as well as
neurons, and found to be co-localized with both Aβ plaques
and tau. Interestingly, it has also been suggested that chronic
inflammation could be the cause for increase in Aβ and tau phos-
phorylation in the brain (Meraz-Ríos et al., 2013). In support
of this, studies on transgenic mice with LPS-induced neuroin-
flammation have shown enhanced intracellular deposition of Aβ
(Sheng et al., 2003; Lee et al., 2008) and tau phosphorylation
(Kitazawa et al., 2005) in the brain of mice. Overall, this suggests
a chain of continuous adverse events in the brain of AD patients,
mediated by IL-1 family of pro-inflammatory cytokines.
INFLAMMASOME MEDIATED INFLAMMATORY PATHWAYS
ASSOCIATED WITH ALZHEIMER’S DISEASE
Recently, the role of inflammasomes, particularly NLRP3, in
oxidative stress-induced neuroinflammation and impaired amy-
loid metabolism seen in AD brains has been evaluated and
recognized (Halle et al., 2008; Marchesi, 2011; Tan et al., 2013).
Neuronal injury caused by insoluble Aβ oligomers and fibrils
releases DAMPs which are sensed by PRRs (NLR domain) on
NALP inflammasomes initiating a chain of events leading to the
maturation of proIL-1β and proIL-18 cytokines and release of
their active forms as the final event (Halle et al., 2008; Salminen
et al., 2009). Moreover, Aβ can interact with neuronal membranes
to create ion channels that allow potassium ion (K+) efflux medi-
ated by ATPase enzyme, activating inflammasomes and in turn
secretion of the active IL-1 family of cytokines (Salminen et al.,
2009; Tschopp and Schroder, 2010). Reduction in intracellular
K+ to 90mM though has been found to be a requirement for the
activation of NLRP3 inflammasomes (higher intracellular con-
centration of K+ inhibits activation of inflammasomes) (Petrilli
et al., 2007). Some authors however, found impaired activity of
Na+/K+ ATPase in AD patients (Hattori et al., 1998) that is
required for the active efflux of K+ across the cell membranes,
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which therefore raises the question whether efflux of K+ is essen-
tial for the activation of inflammasomes. ATPase is required to
catalyze ATP into ADP and a phosphate ion with the release of
energy that activates the purinergic P2X7 receptor. This receptor
in turn decreases intracellular K+ levels (Perregaux and Gabel,
1994; Solle et al., 2001). Purinergic signaling has also been shown
to control the cerebral vascular tone and this has been impli-
cated in learning and memory, locomotor and feeding behavior
and sleep (Burnstock, 2013). Nonetheless, diminished activity of
Na+/K+ ATPase reduces the gradient of ions across the cell mem-
branes causing an excitotoxic cellular response resulting in neu-
ronal death (Hattori et al., 1998). This causes a release of DAMPs
from dead neurons that potentially act as the activators of NLRP3
inflammasome dependent innate immune response (Rubartelli,
2014). It has also been shown that disease-associated extracellular
amyloid and unique protein aggregates caused by inappropriate
oligomerization or misfolding are sensed by NLRP3 inflamma-
somes (Masters and O’Neill, 2011), likely as DAMPs within the
resident macrophages after engulfment in the brain. Research has
also suggested that the brain in AD is under increased oxida-
tive stress and Aβ peptides generates free radicals that together
further enhance neuron degeneration and death (Markesbery,
1997). Mitochondrial ROS released during tissue injury/death
could enhance oxidative damage and signal inflammasome acti-
vation up-regulating pro-inflammatory cytokine levels in brain
(Martinon, 2010; Tschopp and Schroder, 2010; Naik and Dixit,
2011), potentially resulting in neuroinflammation.
Significant pathology and behavioral deficits characteristics of
chronic neuroinflammation do not manifest until advanced age.
This has been attributed to the capacity of the brain to compen-
sate for the presence of chronic neuroinflammation by regulating
the glutamatergic system (Brothers et al., 2013). This suggests
that neuroinflammation in itself does not cause AD; however it
acts as an initiator, enhancer and sustainer of AD disease during
old age which is reinforced by various other etiologies. Since IL-1
cytokines are key contributors of chronic neuroinflammation and
associated neurodegenerative diseases, including AD, inflamma-
somes provide a possible answer for the mechanism of IL-1 action
and the ways in which IL-1 activity is regulated during chronic
neuroinflammation in old age (Allan et al., 2005).
IMMUNE FACTORS ASSOCIATED WITH THE ACTIVITY OF
INFLAMMASOMES
It has been well established that both TNF-α and IL-1β stimu-
late each other’s secretion and exhibit overlapping and synergistic
effects (Akira et al., 1990; Ikejima et al., 1990; Knofler et al.,
1997). For instance, while TNF-α enhances migration of leuco-
cytes in inflamed tissue and promotes apoptosis, IL-1β acts as a
potent pyrogen and decreases the threshold of pain by inducing
the transcription of cyclooxygenase 2 enzyme, thereby enhanc-
ing production of prostaglandins E2, which is responsible for
pain and fever. This raises a possibility that inflammasomes,
which catalyze IL-1β precursors, may stimulate TNF-α secretion
through an indirect pathway. Contrary to this, it has recently
been reported that inflammasomes may also be activated inde-
pendently of PRRs, through TNF-α dependent pathways. TNF-α
has been shown to trigger the activation of caspase 1 and in turn
secretion of IL-1β (Alvarez and Munoz-Fernandez, 2013), sug-
gesting a possible bidirectional cause-effect relationship between
inflammasomes and TNF-α. Although the precise mechanism
for this has not yet been elucidated, this study indicated that
TNF-α may potentially substitute for a TLR mediated stimulus
required for inflammasome activation. Moreover, recent findings
also suggest that TNF-α induces production of IL-33 in ker-
atinocytes (Taniguchi et al., 2013) and regulates expression of
IL-18 in dendritic precursor-like cell line KG-1 and cardiomy-
ocytes (Chandrasekar et al., 2003; Koutoulaki et al., 2010), further
supporting the hypothesis that TNF-α has a role in inflam-
masome activation, although this direct relation between TNF-
α, and IL-18 and IL-33 is yet to be established in the brain.
Furthermore, other cytokines such as Type I interferon (IFN)
gamma have been shown to inhibit caspase-1 cleavage and reduce
IL-1β secretion in rodents (Guarda et al., 2011). Conversely,
although IFN-gamma does not cause inflammation by activat-
ing inflammasomes directly, it has been shown to augment TNF
activity (Dinarello, 2000). Although IL6 is a reliable inflammatory
marker it may not always be directly involved in inflammasome
mediated inflammation as seen in an IL-6 knock in mouse model
(McGeough et al., 2012). Overall, this suggests a complex and
intricate immune pathway mediated by various cytokines that
may be involved in the activation of inflammasomes in the brain,
and resultant neuroinflammation and changes in brain function;
however this requires validation through extensive research.
INFLAMMASOME-INDEPENDENT
NEUROINFLAMMATION-MEDIATED BRAIN PATHOLOGIES
TNF-α is another pro-inflammatory cytokine, in addition to IL-1
cytokines, that has been primarily implicated in neuroinflamma-
tion. Elevated levels of TNF-α in particular have been shown to
cause a reduction in hippocampal volumes through the neurode-
generative TNFR1 pathway (Baune et al., 2012) and can lead to
the development of depressive-like behavior (Eyre et al., 2013).
Glial cells, microglia, and astrocytes, are the primary immune
effector cells and express various cytokines in the CNS (Rothwell
et al., 1996; Hanisch, 2002). Though glial cells are neuropro-
tective, their over expression or sustained stimulation can result
in enhanced production of cytokines (e.g., IL-1β and TNF-α)
(Sawada et al., 1989; Dong and Benveniste, 2001; Hanisch, 2002)
resulting in severe neuroinflammation, neurodegeneration and
subsequent cognitive dysfunction and psychiatric diseases, such
as AD.
While levels of both pro-inflammatory and anti-inflammatory
cytokines in the peripheral circulation and CNS have been
reported to rise during several brain disorders such as depres-
sion, schizophrenia and AD (Schwarz et al., 2001), other humoral
immune factors, such as mitogen-activated protein kinases
(MAPK), C reactive protein (CRP), the complement system and
chemokines have also been reported tomodify brain anatomy and
functions. MAPKs are specific protein kinases (serine-threonine
specific) that elicit pro-inflammatory and immunomodulatory
functions (Lee et al., 1994; Dong et al., 2002). Similarly, CRP is
an acute phase reactant protein which enhances inflammation
and tissue damage by promoting phagocytosis by opsonization
(Du Clos, 2000) and activating the complement system (Padilla
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and Perez, 2003). High levels of CRP in the brain have been
linked to neuroinflammation and associated cognitive impair-
ment and dementia (Kuo et al., 2005), and AD (McGeer et al.,
2000). Researchers have observed upregulation of the comple-
ment system in human brain during AD and other neurode-
generative diseases (McGeer and McGeer, 1995; Yasojima et al.,
1999). The complement system consists of distinct plasma pro-
teins that act as opsonins and initiate a series of inflammatory
responses (Janeway et al., 2001). Chemokines promote neuroin-
flammation by attracting leucocytes to the point of inflammation
(Proost et al., 1996; Mélik-Parsadaniantz and Rostène, 2008).
Neuroinflammation in turn has been implicated for the impair-
ment of brain function (Campbell, 2004; Ownby, 2010; Tansey
and Goldberg, 2010).
Further to the role of inflammasomes and humoral immune
factors, several cellular immune factors such as granulocytes,
monocytes/macrophages, NK cells, and T lymphocytes have also
been shown to have a role in the pathophysiology of neuroin-
flammation (Petersen and Pedersen, 2005, 2006). The role of NK
cells in various brain disorders such as depression, AD and PD
has been reviewed and validated by some researchers (Poli et al.,
2013). Likewise, the exchange of B cells across the BBB has been
reported in patients with multiple sclerosis and associated with
the development of autoimmunity in the CNS (von Büdingen
et al., 2012).
DISCUSSION
NEUROINFLAMMATION AND CYTOKINES
Neuroinflammation is an innate mechanism to ward off any stim-
uli that may be harmful to the host and has been shown to
be mediated by various immune factors, particularly cytokines
(Cacquevel et al., 2004) and chemokines (Ubogu et al., 2006).
In particular, pro-inflammatory cytokines, such as TNF-α and
the IL-1 family of cytokines, are credited for initiating the
inflammatory reactions in the brain in response to an adverse
stimulus, for continuation of neuroinflammation by attract-
ing leucocytes at the site of inflammation and activating other
pro-inflammatory factors, as well as for the anti-inflammatory
pathway by enhancing IL-6 production that in turn stimulates
production and expression of anti-inflammatory cytokines and
immune factors (Cannon, 2000). However, what is more impor-
tant here is the mechanism for the activation of these pro-
inflammatory cytokines in response to an adverse stimulus in
the first instance. While the concept of an increase in concen-
tration of pro-inflammatory cytokines within the brain during
aging and infection is now established, less is known about the
mechanisms of cell signaling that result in the pro-inflammatory
cytokine gradients within the brain.
NLRP INFLAMMASOMES IN NEUROINFLAMMATION
While several theories have been postulated to explain this mech-
anism, recent findings suggest the role of inflammasomes to be
important in particular for the IL-1 family of cytokines (Martinon
and Tschopp, 2006; Stutz et al., 2009; Schroder and Tschopp,
2010). In response to PAMPs and DAMPs, trans-membranous
TLRs that are present in semantic cells such as macrophages
and dendritic cells, interact with NLRs on inflammasomes to
recognize the stimulus, initiating an inflammasome cascade lead-
ing to the release of caspase 1 enzyme in the cytoplasm. Caspase 1
cleaves the pro-forms of the IL-1 family of cytokines to form their
active forms (Inohara et al., 2005; Kanneganti et al., 2007; Franchi
et al., 2009) that may result in neuroinflammation as a result
of increased pro-inflammatory cytokine gradients. Although the
acute neuroinflammatory response includes activation of resi-
dent tissue macrophages in the CNS and subsequent release of
various cytokines and chemokines, this may also cause oxidative
and nitrosative stress, which is a first line preventative mecha-
nism against pathogenic extrinsic and intrinsic proteins and is
less likely to cause long term damage to neurons (Frank-Cannon
et al., 2009). However, it could still result in neurodegenera-
tive changes, as well as in short-term cognitive impairment and
exacerbated sickness behavior, as seen in rodent trials after LPS-
induced acute neuroinflammation characterized by heightened
pro-inflammatory cytokine response (Morimoto et al., 2002;
Huang et al., 2008). Nevertheless, a bigger danger is posed by
chronic neuroinflammation that is generally seen during old age
(Sparkman and Johnson, 2008) and responsible for some brain
pathologies such as depression (Wager-Smith andMarkou, 2011),
AD (Hauss-Wegrzyniak et al., 1998), PD (Tansey and Goldberg,
2010), and multiple sclerosis (Frischer et al., 2009).
For a chronic neuroinflammation to be sustained, the stim-
uli need to be continuous, potent and self-replicating. This could
be explained from the findings that AD patients in old age
suffer from a persistent degenerative condition that involves con-
sistent increases in the various proposed etiologies, be it Aβ
oligomerization or Tau phosphorylation, in the presence of neu-
roinflammation (Meraz-Ríos et al., 2013). A similar scenario
could be plausible in the case of PD where formation of α-
synuclein fibril aggregate increases in the presence of neuroin-
flammation. Accelerated formation of the mutant α-synuclein
fibrils has been linked with the onset of PD (Conway et al.,
1998, 2000). Although it has been shown that aggregated α-
synuclein in microglia-like cells potentially activate the assembly
of NLRP3 inflammasomes by inducing vesicle rupture in THP-1
cells that are sensed as danger signals (Cedillos, 2013), the oppo-
site scenario still need to be studied (Cedillos, 2013). Consistent
findings have also established the link between various etiolo-
gies of depression and neuroinflammation (Maes et al., 1997;
Howren et al., 2009; Dowlati et al., 2010; Hannestad et al.,
2011).
A SHORT NOTE ON THE ROLE OF INFLAMMASOME MEDIATED
NEUROINFLAMMATORY PATHWAYS IN THE COMORBIDITY OF
SYSTEMIC ILLNESSES AND PSYCHIATRIC DISORDERS
High incidences of chronic inflammatory diseases such as can-
cer (Il’yasova et al., 2005), diabetes (De Rekeneire et al., 2006),
osteoarthritis (Stannus et al., 2013), and cardiovascular disease
(Volpato et al., 2001) have been demonstrated by prospective and
correlative studies in aged cohorts. Investigation at the molecu-
lar level suggests increased levels of systemic pro-inflammatory
cytokine IL-1β, in addition to TNF-α and IL-6, and acute
phase proteins (e.g., CRP). Moreover, significant findings have
confirmed an association between age related depression and
level of pro-inflammatory cytokines in the brain (Godbout et al.,
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2008). This suggests a mechanism whereby pro-inflammatory
cytokines migrate from systemic circulation to the brain and
vice versa, especially during old age. Indeed, the pathways for
the transport of pro-inflammatory cytokines to brain from sys-
temic circulation have been described in a review by Capuron
and Miller (2011) (See Figure 4). Rodent studies have shown
increased production and expression of IL-1β in the brain after
LPS-induced systemic inflammation (Cunningham et al., 2005)
and changes inmood and behavior similar to depression after sys-
temic administration of pro-inflammatory cytokines (Pollak and
Yirmiya, 2002). This transport of pro-inflammatory cytokines
into the brain and increase in their expression could be the rea-
son for the comorbidity of systemic illnesses with psychiatric
disorders in old age. Comorbid conditions, such as Type II dia-
betes (Grant and Dixit, 2013; Lee et al., 2013), obesity (Stienstra
et al., 2011), cardiovascular diseases (Connat, 2011), and can-
cer (Fallowfield et al., 2001) with psychiatric illnesses therefore
supports the hypothesis that inflammasomes play a large role in
immunosenescence associated with aging and formation of psy-
chiatric and systemic illnesses with age, the top-most reasons for
deaths worldwide as mentioned by World Health Organization
(2014). However, future research into the role of inflammasomes
in these pathways during aging could possibly explain the link
between age-related psychiatric and systemic illnesses.
The above mentioned link between systemic inflamma-
tory conditions and CNS neurological disorders via activation
of inflammasomes provides a molecular platform on which
to develop therapies to prevent the initiation of those pro-
inflammatory chronic cascades which are detrimental to the CNS.
However, although hypothesized a number of times, it is yet to
be seen if these therapies can be used to treat diseases such as
cancer, diabetes, CVD, and auto-inflammatory disorders (Wilson
and Cassel, 2010) that are major killers worldwide and comor-
bid with brain disorders. Inflammasomes, a molecular platform,
could therefore be regarded as an advent to the innovation of
therapies in the near future.
FIGURE 4 | Cytokines hypothesis of neuroinflammation: Implications in
comorbidity of systemic illnesses with psychiatric disorders.
Pro-inflammatory cytokines can migrate between systemic circulation and
brain in both directions which could explain the comorbidity of systemic
illnesses with psychiatric disorders. There are three pathways for the
transport of pro-inflammatory cytokines from systemic circulation to brain as
described by Capuron and Miller (2011): Cellular, Humoral, and Neural.
Moreover, PAMPs and DAMPs from trauma, infection, and metabolic waste
can prime glial cells to express pro-inflammatory cytokines TNF-α, IL-1β, and
IL-6. When expressed, these cytokines activates granulocytes,
monocytes/macrophages, Natural Killer, and T cells and together contribute
to the pathophysiology of neuroinflammation. Chronic neuroinflammation
could result in neurodegeneration and associated psychiatric disorders. These
pro-inflammatory cytokines also stimulate production and expression of
anti-inflammatory cytokine by glial cells that function as negative feedback to
reduce the expression of pro-inflammatory cytokines, subsiding the
neuroinflammation. MCP-1, Monocyte chemoattractant protein-1; CP, Choroid
plexus; CVO, Circumventricular organ.
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CONCLUDING REMARKS
Taken together, it is clear that the discovery of the role of inflam-
masomes in neuroinflammation has opened an array of research
opportunities to investigate the inflammasome targeted therapies
for age-related and pathological changes in the brain. It is also
clear from the above discussion that the inflammasome activation
pathway is complex and may involve the role of other immune
factors such as cytokines, as well as mutant protein aggregates
such as Aβ and α-synuclein fibrils. However, further research
into these mechanisms and inflammasome-targeted therapies is
advisable for constructing and assessing the complete profile of
inflammasome-driven inflammatory pathways in brain.
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